Randox's biochip array technology is suitable for the detection of drugs in oral fluid within areas such as workplaces, prisons and drug rehabilitation clinics.
Unlike rapid tests, the biochip array technology is claimed to offer a diagnostic-grade testing solution with reliable and reproducible results.
Biochip arrays offer a one-shot multiplex assay, detecting up to 97 drugs and drug metabolites from an undivided oral fluid sample.
Matrix-dedicated kits ensure excellent assay performance and specificity, even at lower drug concentrations, according to the company.
Randox biochip arrays meet the limit-of-detection requirements for both the European Workplace Drug Testing Society guidelines for oral fluid testing and the Australian and New Zealand procedures for specimen collection and the detection and quantification of drugs in oral fluid.
The efficient biochip arrays also provide a rapid turnaround time, which is said to be advantageous for on-site workplace drug testing.
In comparison, a four-plate automated ELISA system would require 13 times longer to process the same results.
Randox recently launched a point-of-collection biochip analyser - the Evidence Multistat - which processes multiple results in less than 20 minutes.
As it is a multi-matrix biochip platform, a number of sample types - including oral fluid, whole blood, urine and post-mortem tissue - can be run on the system.
The Randox line of Evidence immunoassay analysers generates quality control data automatically with every run, ensuring that each test has been carried out successfully.
With a number of benefits to be gained from on-site testing, oral fluid will continue to be put into practice for drugs-of-abuse screening.
